Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. Grünwald V, et al. Among authors: pirotta n. Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29. Eur J Cancer. 2012. PMID: 21803569 Clinical Trial.
Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Escudier B, Grünwald V, Ravaud A, Ou YC, Castellano D, Lin CC, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi M, Angevin E. Escudier B, et al. Among authors: pirotta n. Clin Cancer Res. 2014 Jun 1;20(11):3012-22. doi: 10.1158/1078-0432.CCR-13-3006. Epub 2014 Apr 1. Clin Cancer Res. 2014. PMID: 24691021 Clinical Trial.
Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Guo J, Huang Y, Zhang X, Zhou F, Sun Y, Qin S, Ye Z, Wang H, Jappe A, Straub P, Pirotta N, Gogov S. Guo J, et al. Among authors: pirotta n. BMC Cancer. 2013 Mar 21;13:136. doi: 10.1186/1471-2407-13-136. BMC Cancer. 2013. PMID: 23514360 Free PMC article. Clinical Trial.
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML. Schaaf LJ, et al. Among authors: pirotta n. Clin Cancer Res. 2006 Jun 15;12(12):3782-91. doi: 10.1158/1078-0432.CCR-05-2152. Clin Cancer Res. 2006. PMID: 16778106 Clinical Trial.
Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients.
Dautzenberg B, Castellani P, Pellegrin JL, Vittecoq D, Truffot-Pernot C, Pirotta N, Sassella D. Dautzenberg B, et al. Among authors: pirotta n. Antimicrob Agents Chemother. 1996 Jul;40(7):1722-5. doi: 10.1128/AAC.40.7.1722. Antimicrob Agents Chemother. 1996. PMID: 8807071 Free PMC article. Clinical Trial.
17 results